Skip to main content
Premium Trial:

Request an Annual Quote

American Oncology Network, VieCure Ink Precision Oncology Partnership

NEW YORK – American Oncology Network said on Wednesday that it has partnered with VieCure to expand precision oncology adoption throughout its network of oncologists and care providers.

Through the strategic collaboration, AON — a network of 105 physicians and 79 nurse practitioners and physician assistants across 16 US states, primarily in community settings — will use VieCure's cloud-based, artificial intelligence-informed clinical decision support technology to help generate personalized treatment plans. The data that AON shares with VieCure, including longitudinal patient outcomes data and molecular information, will help VieCure to continue evolving its technology platform.

The Denver-based startup's platform uses AI to combine patient data with clinical trial data to create treatment plans and also includes a clinical content library to help oncologists stay abreast of new research; a patient-facing app; an electronic medical records system; analytics tools; and telemedicine capabilities.

Together, the partners will use the data and technology platform to assess personalized treatments, create new value-based care solutions, improve patient outcomes, and help guide next-generation prevention, screening, diagnostic, and therapeutic opportunities.

Additionally, AON and VieCure will use the data and insights they generate to ink industry partnerships on initiatives related to clinical research, radiation therapy, radioligand therapy, pharmaceuticals, and molecular diagnostics.

The partnership is structured around three goals, one being the use of next-generation sequencing, targeted therapy, immunotherapy, and new therapies such as radio ligands; one being the transition to a value-based care model; and one being an increase in patient involvement in their care.

To accomplish these goals, AON and VieCure aim to create new technological innovations, advance access to clinical trials and new therapies, centralize precision oncology infrastructure, and make it easier to order NGS and interpret and apply results.

Oncologists "want to make the right decisions at the right time, but they're often overwhelmed by data, which is poorly accessible and manageable, leading to clinical workflow burdens, which get in the way of achieving the best outcomes for their patients," Stephen Divers, AON's advisory board chairman, said in a statement. "They need a technology solution that helps simplify cancer's complexities and empowers them to do their best."